Biohaven Ltd. is a global clinical stage biopharmaceutical ... The company was founded on May 2, 2022 and is headquartered in New Haven, CT.

These three therapeutic strategies could provide new approaches to a diverse set of unmet needs. Biohaven’s lead compounds are the CGRP receptor antagonist rimegepant and the glutamate modulator ...

The company’s broad experience with the development of new solutions for neurologic disorders, including a number of orphan diseases, makes Biohaven a partner of choice for potential ...

Troriluzole has a well-established safety profile and if approved, would be the first and only FDA-approved treatment for SCA; subject to receipt of FDA approval, Biohaven is prepared to commercialize ...